Tuesday, April 22, 2014 12:54:38 PM
yes..designed to assist kblb in the transition..not that they would be doing the commercial production in tons...just commercial production in kilos for samples...
"The purpose of the program is to verify scalability and favorable production economics of Monster Silk™, to significantly increase production, and to form the basis of large scale commercial production of the Company's recombinant spider silks."
verify..increase production..."form the basis of large scale production"...nothing about tons..
"The pilot program was designed to "transition Kraig from laboratory scale production to commercial scale."
kim had already made the metric tons by mid year prediction by this point...no where does he indicate that he intended them to come from here...he was travelling to Vietnam for the metric ton capacity imo...
"Nowhere did it state that the facility lacks the capacity to produce on a commercial-scale basis."
no where did it state that it had the capacity for tonnage... it did however SPECIFICALLY state that they could produce commercial SAMPLES of ms...
"I could see where one would think that commercial-scale production couldn't take place there but that isn't the case."
commercial scale production of samples is taking place there...just not tonnage imo...
Recent KBLB News
- Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 11/22/2023 09:31:54 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 11/16/2023 09:30:34 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/13/2023 09:43:51 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 09/11/2023 08:30:50 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 09/08/2023 04:15:15 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 09/01/2023 08:30:52 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2023 08:35:05 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM